We are live on
!
Find out more
CI
Clal Insurance Portfolio holdings
AUM
$22.3B
1-Year Est. Return
79.91%
This Fund
S&P 500
This Quarter
Est. Return
+1.91%
1 Year Est. Return
+79.91%
3 Year Est. Return
+201.85%
5 Year Est. Return
+220.25%
10 Year Est. Return
+954.66%
AUM
$3.76B
AUM Growth
-$34.7M
(-0.91%)
Cap. Flow
-$64.8M
Cap. Flow
% of AUM
-1.72%
Top 10 Holdings %
Top 10 Hldgs %
65.5%
Holding
82
New
17
Increased
17
Reduced
20
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P Biotech ETF
XBI
|
+$123M |
| 2 |
Vanguard S&P 500 ETF
VOO
|
+$68.1M |
| 3 |
Perrigo
PRGO
|
+$46M |
| 4 |
MLNX
Mellanox Technologies, Ltd.
MLNX
|
+$42.5M |
| 5 |
The Mosaic Company
MOS
|
+$36.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Biotechnology ETF
IBB
|
+$130M |
| 2 |
iShares US Pharmaceuticals ETF
IHE
|
+$116M |
| 3 |
Viatris
VTRS
|
+$60.9M |
| 4 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$40.7M |
| 5 |
XYZ
Block Inc
XYZ
|
+$37.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 55.79% |
| 2 | Technology | 16.53% |
| 3 | Financials | 6.72% |
| 4 | Industrials | 5.99% |
| 5 | Healthcare | 5.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Amdocs
DOX
$6.51B
| $23.5M | 0.63% |
352,812
-222,915
| -39% | -$15M |
|
27
Kornit Digital
KRNT
$657M
| $23.5M | 0.62% |
1,818,717
+459,452
| +34% | +$6.51M |
|
28
Nice
NICE
$6.09B
| $19.1M | 0.51% |
203,868
| – | – |
|
|
VRNT
29
DELISTED
Verint Systems
VRNT
| $19.1M | 0.51% |
878,790
| – | – |
|
|
NVMI
30
Nova
NVMI
$10.7B
| $16.2M | 0.43% |
597,960
| – | – |
|
31
UroGen Pharma
URGN
$2.04B
| $14.1M | 0.37% |
283,500
+279,039
| +6,255% | +$14M |
|
32
Caesarstone
CSTE
$104M
| $12.3M | 0.33% |
624,251
| – | – |
|
33
Allot
ALLT
$399M
| $11.9M | 0.32% |
2,207,993
| – | – |
|
|
MGIC
34
DELISTED
Magic Software Enterprises
MGIC
| $11.2M | 0.3% |
1,315,872
| – | – |
|
35
Elbit Systems
ESLT
$34.3B
| $11M | 0.29% |
90,272
| – | – |
|
36
Teva Pharmaceuticals
TEVA
$45.7B
| $10.7M | 0.28% |
624,432
-900,000
| -59% | -$17.6M |
|
|
37
Viatris
VTRS
$19.1B
| $7.49M | 0.2% |
181,937
-1,427,998
| -89% | -$60.9M |
|
|
SPNS
38
DELISTED
Sapiens International
SPNS
| $6.86M | 0.18% |
803,583
+461,710
| +135% | +$4.89M |
|
|
SODA
39
DELISTED
SodaStream International Ltd
SODA
| $6.41M | 0.17% |
69,787
| – | – |
|
|
CYBR
40
DELISTED
CyberArk
CYBR
| $6.23M | 0.17% |
122,116
-50,000
| -29% | -$2.33M |
|
41
Alphabet (Google) Class C
GOOG
$4.18T
| $5.19M | 0.14% |
100,560
| – | – |
|
42
State Street Energy Select Sector SPDR ETF
XLE
$43.3B
| $4.45M | 0.12% |
+132,000
| New | +$4.67M |
|
|
GZT
43
DELISTED
Gazit-globe Ltd
GZT
| $4.42M | 0.12% |
449,978
| – | – |
|
44
Vanguard FTSE Europe ETF
VGK
$30.1B
| $4.36M | 0.12% |
75,004
-68
| -0.1% | -$4.08K |
|
45
Ituran Location and Control
ITRN
$1.02B
| $4.08M | 0.11% |
130,719
+38,500
| +42% | +$1.32M |
|
46
Sony
SONY
$140B
| $3.99M | 0.11% |
413,050
| – | – |
|
47
Palo Alto Networks
PANW
$307B
| $3.63M | 0.1% |
120,000
+103,668
| +635% | +$2.88M |
|
48
WisdomTree Japan SmallCap Dividend Fund
DFJ
$450M
| $3.61M | 0.1% |
+44,363
| New | +$3.62M |
|
49
Ryanair
RYAAY
$26.9B
| $3.51M | 0.09% |
71,513
| – | – |
|
50
WisdomTree Trust WisdomTree Emerging Markets Quality Dividend Growth Fund
DGRE
$148M
| $2.49M | 0.07% |
91,940
| – | – |
|
Similar funds
LF
DCP
CS
CIG
TAF
SOMRS
MIM
Clal Insurance's Q1 2018 Portfolio in Review
As of Q1 2018, Clal Insurance held 82 positions worth $3.76B, down 0.91% from $3.8B the previous quarter. Its ten largest holdings account for 66% of the portfolio.
Clal Insurance's Q1 2018 filing shows 17 new, 17 increased, 20 reduced and 9 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 1,352,197 shares worth $119M. The largest sale was iShares Biotechnology ETF, an estimated $130M.
By sector, the portfolio is most concentrated in Miscellaneous at 56% of assets, down from 59% a quarter earlier, followed by Technology and Financials.
- Clal Insurance's largest Q1 2018 buy was State Street SPDR S&P Biotech ETF: 1,352,197 shares worth $119M.
- Clal Insurance added most to Vanguard S&P 500 ETF in Q1 2018, an estimated $68.1M increase.
- Clal Insurance's biggest Q1 2018 reduction was iShares Biotechnology ETF, cutting an estimated $130M.
- Clal Insurance fully exited iShares US Pharmaceuticals ETF in Q1 2018, selling an estimated $116M.
- Clal Insurance's ten largest holdings make up 66% of its $3.76B portfolio in Q1 2018.
- Clal Insurance opened 17 new positions and closed 9 in Q1 2018.
- Clal Insurance's portfolio value fell 0.91% quarter-over-quarter to $3.76B.
Based on Clal Insurance's 13F filing for Q1 2018, filed 2 May 2018.